Mervyn’s Petcare, Inc.
A cat-first health supplement company developing science-based, compliance-friendly products designed specifically for cats.
Market:
42 million U.S. households have cats, yet fewer than 25% of pet supplements are designed specifically for them. Most are sold as treats. The global pet supplement market is valued at $2.5B and growing. Mervyn’s Petcare aims to lead the underserved feline health segment with products tailored to cats’ unique needs and backed by science.
Technology:
We develop functional health supplements targeting the most common feline health issues. Our products are formulated in collaboration with veterinarians and nutritionists, and delivered in cat-friendly formats.
Advantages:
- Cat-specific product line
- Developed with veterinary advisors
- Backed by scientific literature
- Clear regulatory positioning as veterinary supplements (not treats)
Development Stage:
- Commercial-ready
Patents Issued:
- U.S. trademarks filed
Contact:
Website: https://www.mervynspet.com
Email: robert@mervynspet.com
Current Portfolio Companies
- Anaco
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- Diatom Biolab
- Eximius Diagnostics
- Giant BioSystems
- Hikari Medical Technologies
- ImmunoVec
- MedStat AI Inc.
- Mervyn's Petcare, Inc.
- Meteor Biotech, LLC
- My Block Skin, Inc.
- Nanomega CryoAI
- NEXT-TFX, Inc.
- Paralos Bioscience Inc.
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Protean Research, Inc.
- Purpose Bio
- RaizDx
- RiboForge
- Saku Biosciences, Inc.
- SolGrapH, Inc.
- Sorriso Pharmaceuticals
- Thermeutics, Inc.
- Veergen, Inc.
- Yuyu Bio, Inc.